Pharma is riding a vaccine high, but reputational risks loom
Suspensions of AstraZeneca’s jab because of blood clot concerns are a harbinger of challenges to come
Pharmaceutical companies have never had it so good. The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the industry is winning praise for cooperation.
But the decision this week by some governments to suspend use of the Oxford/AstraZeneca vaccine because of fears of possible blood clots shows just how fragile public trust can be. What has been a public relations triumph could, if handled badly, turn out to be a trap...